ESSA Pharma Other Operating Expenses Over Time
| EPIX Stock | USD 1.69 0.01 0.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ESSA Pharma Performance and ESSA Pharma Correlation. ESSA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Return On Assets (0.15) | Return On Equity (0.20) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Operating Expenses Analysis
Compare ESSA Pharma and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Other Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 8.6 M | 8.6 M | 8.6 M | 8.6 M | 8.6 M | 8.6 M | 8.6 M | 8.6 M | 8.6 M | 26.7 M | 29.5 M | 37.8 M | 54.8 M | 50.6 M | 38.1 M |
| DMAC | 637.3 K | 6.7 M | 10.1 M | 7.4 M | 4.8 M | 1.3 M | 2.5 M | 4.3 M | 6 M | 10.7 M | 12.5 M | 13.6 M | 14 M | 21.3 M | 22.3 M |
| VALN | 4.4 M | 15.4 M | 16.3 M | 52.6 M | 60.7 M | 98.3 M | 136.5 M | 109.2 M | 106.8 M | 126.9 M | 165.4 M | 409.5 M | 474.7 M | 235.8 M | 118.8 M |
| VANI | 17.4 M | 17.4 M | 17.4 M | 19.6 M | 24.6 M | 29 M | 37.2 M | 36.6 M | 41.5 M | 34 M | 9.2 M | 13.3 M | 21.2 M | 27 M | 20.7 M |
| DNLI | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 87.4 M | 90.1 M | 175.5 M | 239.9 M | 272.9 M | 344.4 M | 449.2 M | 527.2 M | 269.3 M |
| DNTH | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 35.7 M | 60 M | 83 M | 78.7 M | 14.6 M | 36.1 M | 51 M | 50.6 M |
| DOMH | 6.5 M | 5.2 M | 3.5 M | 15.4 M | 30.6 M | 11.4 M | 6.7 M | 5.1 M | 4.5 M | 5.7 M | 6.5 M | 9.4 M | 14.3 M | 23.8 M | 25 M |
| VCEL | 12.1 M | 29.1 M | 33.8 M | 21 M | 52.3 M | 67.8 M | 71 M | 78.9 M | 94.8 M | 129.1 M | 121.8 M | 164 M | 181.4 M | 204 M | 214.2 M |
| VCNX | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 21.2 M | 28 M | 32.5 M | 28.4 M | 23.4 M | 20 M | 23.5 M | 19.8 M |
| VCYT | 17.9 M | 17.9 M | 30.6 M | 45.1 M | 67.2 M | 83 M | 93.9 M | 98.5 M | 114.2 M | 135.5 M | 152.9 M | 301.4 M | 337.6 M | 446.8 M | 469.2 M |
ESSA Pharma and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Other Operating Expenses description
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ESSA Pharma. It is also known as ESSA Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.My Equities
My Current Equities and Potential Positions
| ESSA Pharma | EPIX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | British Columbia; Canada |
| Exchange | NASDAQ Exchange |
USD 1.69
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.